Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 9/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.37 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.36 |
| ▸ | PDE4A | P27815 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | METAP2 | P50579 | 1/20 | 0.35 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.35 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.34 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.34 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17151303 | 0.87 | GRM2 (0.41) | GRM2DYRK1APDE3APDE4ACYP3A4 | |
| SCHEMBL18811846 | 0.84 | GRM2 (0.38) | GRM2DYRK1APDE3APDE4ACYP3A4 | |
| SCHEMBL18077739 | 0.82 | PDE3A (0.41) | GRM2DYRK1APDE3APDE4ACYP3A4 | |
| SCHEMBL18811825 | 0.78 | ROCK2 (0.34) | — | |
| SCHEMBL18811901 | 0.77 | BRD4 (0.38) | GRM2 | |
| SCHEMBL18077764 | 0.74 | ABL1 (0.36) | — | |
| SCHEMBL17151307 | 0.73 | SCN5A (0.40) | GRM2PDE3APDE4ACYP3A4HPGD | |
| SCHEMBL18077793 | 0.70 | CYP1A2 (0.37) | CYP3A4CYP1A2MCHR1 | |
| SCHEMBL16474644 | 0.69 | GRM2 (0.42) | GRM2PDE3APDE4ACYP3A4HPGD | |
| SCHEMBL16474431 | 0.68 | MAPT (0.41) | MCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170121345-A1 | ANTI-FIBROTIC PYRIDINONES | GENENTECH, INC. | 2017-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170121345-A1 | ANTI-FIBROTIC PYRIDINONES | MMP1, COL1A1, COL2A1 | GRM2 4047/4885DYRK1A 4514/4885PDE3A 576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.